Glycoconjugate vaccines to prevent group B streptococcal infections

被引：33

作者：

Paoletti, LC ^{[1
]}

Kasper, DL ^{[1
]}

机构：

[1] Harvard Univ, Brigham & Womens Hosp, Sch Med, Channing Lab,Dept Med, Boston, MA 02115 USA

来源：

EXPERT OPINION ON BIOLOGICAL THERAPY | 2003年 / 3卷 / 06期

基金：

美国国家卫生研究院;

关键词：

clinical trials; group B Streptococcus; maternal vaccine; prevention of colonisation; vaccines;

D O I：

10.1517/14712598.3.6.975

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Group B Streptococcus (GBS) is an opportunistic pathogen of humans. At-risk populations include neonates born to colonised mothers, peripartum women, diabetics, and the elderly with underlying illnesses. Vaccines to prevent GBS disease have been developed by coupling purified capsular polysaccharide (CPS) antigen of GBS with an immunogenic protein carrier. Glycoconjugate vaccines against all nine currently identified GBS serotypes have been synthesised and shown to be immunogenic in mice, rabbits and baboons in preclinical trials. Healthy adults have safely received conjugate vaccines prepared with GBS types Ia, Ib, II, III, and V CPSs in Phase I and II clinical trials. These vaccines elicited CPS-specific antibody that opsonised GBS for in vitro killing by human peripheral blood leukocytes in the presence of complement. Results from these preclinical and clinical studies strongly suggest that GBS conjugate vaccines will be effective in preventing diseases caused by GBS.

引用

页码：975 / 984

页数：10

共 81 条

[41] Bacterial vaccines and serotype replacement:: Lessons from Haemophilus influenzae and prospects for Streptococcus pneumoniae [J].

Lipsitch, M .

EMERGING INFECTIOUS DISEASES, 1999, 5 (03) :336-345

[42] Invasive group B streptococcal infections in Finland:: A population-based study [J].

Lyytikäinen, O ;

Nuorti, JP ;

Halmesmäki, E ;

Carlson, P ;

Uotila, J ;

Vuento, R ;

Ranta, T ;

Sarkkinen, H ;

Ämmälä, M ;

Kostiala, A ;

Järvenpää, AL .

EMERGING INFECTIOUS DISEASES, 2003, 9 (04) :469-473

[43] MATERNAL IMMUNIZATION OF MICE WITH GROUP-B STREPTOCOCCAL TYPE-III POLYSACCHARIDE-BETA C-PROTEIN CONJUGATE ELICITS PROTECTIVE ANTIBODY TO MULTIPLE SEROTYPES [J].

MADOFF, LC ;

PAOLETTI, LC ;

TAI, JY ;

KASPER, DL .

JOURNAL OF CLINICAL INVESTIGATION, 1994, 94 (01) :286-292

[44] Use of a dynamic in vitro attachment and invasion system (DIVAS) to determine influence of growth rate on invasion of respiratory epithelial cells by group B Streptococcus [J].

Malin, G ;

Paoletti, LC .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (23) :13335-13340

[45]

Mattheis MJ, 1998, VACCINES - FROM CONCEPT TO CLINIC, P89

[46]

McDonald H M, 2000, Infect Dis Obstet Gynecol, V8, P220, DOI 10.1155/S1064744900000314

[47] Association of sexual activity with colonization and vaginal acquisition of group BStreptococcus in nonpregnant women [J].

Meyn, LA ;

Moore, DM ;

Hillier, SL ;

Krohn, MA .

AMERICAN JOURNAL OF EPIDEMIOLOGY, 2002, 155 (10) :949-957

[48] CARRIAGE OF HAEMOPHILUS-INFLUENZAE TYPE-B IN CHILDREN AFTER WIDESPREAD VACCINATION WITH CONJUGATE HAEMOPHILUS-INFLUENZAE TYPE-B VACCINES [J].

MOHLEBOETANI, JC ;

AJELLO, G ;

BRENEMAN, E ;

DEAVER, KA ;

HARVEY, C ;

PLIKAYTIS, BD ;

FARLEY, MM ;

STEPHENS, DS ;

WENGER, JD .

PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1993, 12 (07) :589-593

[49]

Paoletti Lawrence C, 2002, Semin Neonatol, V7, P315, DOI 10.1053/siny.2002.0114

[50] Therapeutic potential of human antisera to group B streptococcal glycoconjugate vaccines in neonatal mice [J].

Paoletti, LC ;

Pinel, J ;

Rodewald, AK ;

Kasper, DL .

JOURNAL OF INFECTIOUS DISEASES, 1997, 175 (05) :1237-1239

← 1 2 3 4 5 6 7 8 9 →